Recombinant allergens for immunotherapy: A Der p 2 variant with reduced IgE reactivity retains T-cell epitopes☆☆☆★★★ (original) (raw)

This research explores a recombinant variant of the mite allergen Der p 2, named C73-78, which has been engineered to exhibit significantly reduced IgE reactivity while retaining T-cell epitope stimulation in allergic individuals. The study involves both quantitative intradermal skin testing and proliferation assays, demonstrating decreased skin test sensitivity to the variant in atopic subjects. The findings suggest that such modified allergens could enhance safety in immunotherapy, allowing for accelerated treatment protocols with reduced risk of allergic reactions.